The analysis of dimethyl fumarate is a cost-effective and cost-saving treatment approach from the healthcare and societal perspective. The analysis demonstrates that dimethyl fumarate is cost-effective and cost saving from a healthcare and societal perspective at a yearly horizon of 50 years, considering a discount rate of 5%, for both costs and benefits. The analysis was conducted from the societal perspective, assuming a time horizon relevant to the Portuguese setting. Unit costs were obtained from official sources. The analysis considered the clinical trials and London Ontario database. Utility weights for patients and conversion to SPMS or progression to EDSS were used. Clinical inputs for active treatments were based on the Expanded Disability Status Scale (EDSS). At any time, patients have an enabling of 50 years and a discount rate of 5%, for both costs and benefits.

The analysis demonstrates that dimethyl fumarate is a cost-effective and cost-saving treatment approach from the healthcare and societal perspective. The analysis was conducted from the societal perspective, assuming a time horizon relevant to the Portuguese setting. Unit costs were obtained from official sources. The analysis considered the clinical trials and London Ontario database. Utility weights for patients and conversion to SPMS or progression to EDSS were used. Clinical inputs for active treatments were based on the Expanded Disability Status Scale (EDSS). At any time, patients have an enabling of 50 years and a discount rate of 5%, for both costs and benefits.